Leiden, The Netherlands, March 22, 2007 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced it has completed an influenza alliance with Taiwanese- based ADImmune Corporation. Under the terms of the deal, ADImmune will use Crucell’s virosome technology to produce a virosomal adjuvanted influenza vaccine for specified markets: Taiwan, Japan and Macau. Additionally, ADImmune will produce influenza antigen, which Crucell may purchase for the production of its vaccine product, Inflexal® V. Crucell will obtain a 20% equity stake in ADImmune. Financial details were not disclosed.
